Structure Therapeutics, Inc. Sponsored ADR (GPCR) Price & Analysis

Compare

1,016 Followers

GPCR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.22 - $45.37

Previous CloseN/A

Volume219.80K

Average Volume (3M)762.70K

Market Cap

$1.05B

Enterprise Value$11.32B

Total Cash (Recent Filing)$836.88M

Total Debt (Recent Filing)$7.59M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Aug 07, 2025

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding57,536,750

10 Day Avg. Volume867,519

30 Day Avg. Volume762,703

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-99.14

Price to Sales (P/S)0.00

P/FCF Ratio-246.69

Enterprise Value/Market Cap10.82

Enterprise Value/Revenue4.26K

Enterprise Value/Gross Profit-48.87K

Enterprise Value/Ebitda-18.81

Forecast

1Y Price Target

$78.73

Price Target Upside332.82% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Structure Therapeutics, Inc. Sponsored ADR News

PremiumThe Fly

Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

14d ago

GPCR

PremiumCompany Announcements

Structure Therapeutics Holds 2025 Annual Shareholders Meeting

29d ago

GPCR

PremiumRatings

Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating

2M ago

GPCR

PremiumThe Fly

Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright

2M ago

GPCR

PremiumRatings

Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating

2M ago

GPCR

PremiumRatings

Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning

3M ago

GPCR

PremiumRatings

Promising Developments in Weight Management Propel Buy Rating for Structure Therapeutics

3M ago

GPCR

PremiumCompany Announcements

Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs

3M ago

GPCR

See All GPCR News

See All News >

Bulls Say, Bears Say

Bulls Say

Cash PositionThe company has a cash runway extending to 2027, ensuring financial stability to support ongoing and future development activities.

Competitive AdvantageAleniglipron's structural uniqueness and safety profile offer a competitive edge by avoiding the pitfalls of danuglipron’s toxicity.

Therapeutic PotentialOral GLP-1 receptor agonists can become first-line drugs for T2D and obesity, offering significant therapeutic potential and opportunities in the market.

Bears Say

Competitive LandscapeUncertainty exists regarding how oral GLP-1 therapies will position alongside established injectable formulations in the obesity treatment market.

Market ChallengesPharmacy benefit manager access remains a challenge for new entrants in the oral obesity treatment space, potentially limiting market penetration.

Regulatory And Development RisksQuestions remain whether competitor molecules with a similar danuglipron-like backbone will encounter similar issues, which could impact the market dynamics.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

11.96% Insiders

30.98% Mutual Funds

<0.01% Other Institutional Investors

56.12% Public Companies and

Individual Investors

Detailed Ownership Overview >

GPCR FAQ

What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?

Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $45.37 in the past 12 months.

What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?

Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.05B.

When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?

Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 07, 2025 which is in 14 days.

How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?

Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 08, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.241 by -$0.029.

Is Structure Therapeutics, Inc. Sponsored ADR overvalued?

According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?

Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.

What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?

Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.28.

How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?

Structure Therapeutics, Inc. Sponsored ADR has 57,536,750 shares outstanding.

What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?

Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.241. Following the earnings report the stock price went down -4.661%.

Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?

Currently, no hedge funds are holding shares in GPCR

Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score

Underperform

Fundamentals

Return on Equity

-22.88%

Trailing 12-Months

Asset Growth

89.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a biopharmaceutical company focused on discovering and developing innovative treatments for patients with unmet medical needs. The company primarily operates within the healthcare sector, specializing in the development of novel drug candidates targeting G protein-coupled receptors (GPCRs), which play a crucial role in various physiological processes and diseases. Structure Therapeutics leverages advanced technologies and scientific expertise to design and develop therapeutic compounds aimed at addressing conditions such as metabolic disorders, inflammation, and other significant health challenges.

GPCR Stock 12 Month Forecast

Average Price Target

$78.73

▲(332.82%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","121":"$121","40.75":"$40.8","67.5":"$67.5","94.25":"$94.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,40.75,67.5,94.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.51,28.163076923076925,35.816153846153846,43.46923076923077,51.12230769230769,58.77538461538461,66.42846153846153,74.08153846153846,81.73461538461538,89.3876923076923,97.04076923076923,104.69384615384615,112.34692307692308,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.51,24.98846153846154,29.46692307692308,33.94538461538462,38.423846153846156,42.902307692307694,47.38076923076923,51.85923076923078,56.33769230769231,60.81615384615385,65.29461538461538,69.77307692307693,74.25153846153847,{"y":78.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.51,22.77846153846154,25.04692307692308,27.315384615384616,29.583846153846153,31.852307692307694,34.12076923076923,36.38923076923077,38.65769230769231,40.926153846153845,43.19461538461539,45.463076923076926,47.73153846153846,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >